Vaccine Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed stage IIIA or IIIB non-small cell lung cancer (NSCLC) with one of the following p53 mutations:
• * Point mutation altering the protein sequence
• * Frame-shift mutation with the generation of a novel sequence
• No significant pleural effusions visible on plain chest radiography
• Must have completed or plan to undergo curative intent therapy for NSCLC
• * At least 2 courses of neoadjuvant chemotherapy for patients with known N2 or N3 resectable disease OR
• * At least 55 Gy radiotherapy with concurrent or sequential chemotherapy for patients with unresectable disease
• * Patients with incidental N2 or N3 disease at time of surgery may receive optional adjuvant chemotherapy and radiotherapy
• PATIENT CHARACTERISTICS:
• Age:
• Not specified
• Performance status:
• ECOG 0-1
• Life expectancy:
• Not specified
• Hematopoietic:
• Lymphocyte count greater than 475/mm\^3
• Granulocyte count greater than 1,000/mm\^3
• Platelet count greater than 100,000/mm\^3
• Hepatic:
• Bilirubin less than 2.0 mg/dL
• SGOT less than 3 times normal
• Albumin at least 3.0 g/dL
• No signs of acute hepatitis B infection
• * Hepatitis B surface antigen positive allowed provided there are no signs of chronic active hepatitis
• No prior hepatitis C infection
• Renal:
• Creatinine less than 2.5 mg/dL
• Calcium less than 11.0 mg/dL (corrected for albumin)
• Cardiovascular:
• No myocardial infarction or significant ventricular arrhythmias within the past 6 months
• Other:
• No other malignancy within the past 5 years unless curatively treated and probability of recurrence is less than 5%
• HIV negative
• No psychiatric or other condition that would preclude study
• No serious ongoing infection
• No other serious medical condition that would limit life expectancy to less than 2 years
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• Not specified
• Chemotherapy:
• See Disease Characteristics
• At least 4 weeks since prior chemotherapy and no anticipated need for chemotherapy for at least 2 months after vaccinations
• Endocrine therapy:
• At least 4 weeks since prior supraphysiologic steroids and no anticipated need for steroid therapy for at least 2 months after vaccinations
• Radiotherapy:
• See Disease Characteristics
• At least 4 weeks since prior radiotherapy and no anticipated need for radiotherapy for at least 2 months after vaccinations
• Surgery:
• See Disease Characteristics
• Other:
• No influenza vaccination if egg allergy present
• At least 4 weeks and no greater than 24 weeks since completion of all prior modalities for primary therapy